Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scotland Okays First ILAP Drugs For Reimbursement

Executive Summary

The Scottish Medicines Consortium has recommended Gilead’s Trodelvy, Amgen’s Lumykras and Pfizer’s Lorviqua for use on the Scottish National Health Service.

You may also be interested in...



Reimbursement Rejection On Cost Grounds For “Highly Effective” Trodelvy In England

In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.

UK Should Look To France To Speed Up Access To Innovative Medicines

Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.

UK Regulator Issues 41 ‘Innovation Passports’ In First Year Of New Pathway

The UK’s ILAP, a post-Brexit scheme introduced in 2021 to accelerate the development of, and access to, new innovative medicines, proved popular in its first year of operation. A total of 71 applications were received last year from companies wanting to take advantage of the regulatory advice, tools and flexibilities on offer.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel